ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 114 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $81 | -49.1% | 40,055 | -23.6% | 0.00% | -50.0% |
| Q1 2023 | $159 | +169.5% | 52,397 | +106.4% | 0.00% | +100.0% |
| Q4 2022 | $59 | -99.9% | 25,381 | -13.9% | 0.00% | 0.0% |
| Q3 2022 | $56,000 | -3.4% | 29,475 | +37.0% | 0.00% | 0.0% |
| Q2 2022 | $58,000 | +48.7% | 21,518 | +62.5% | 0.00% | – |
| Q1 2022 | $39,000 | -53.6% | 13,244 | -38.8% | 0.00% | – |
| Q4 2021 | $84,000 | -96.7% | 21,625 | -96.4% | 0.00% | -100.0% |
| Q3 2021 | $2,571,000 | +4661.1% | 599,349 | +1578.8% | 0.01% | – |
| Q3 2019 | $54,000 | -64.5% | 35,701 | -51.2% | 0.00% | -100.0% |
| Q2 2019 | $152,000 | -26.2% | 73,098 | +27.2% | 0.00% | -50.0% |
| Q1 2019 | $206,000 | +11.4% | 57,454 | +18.8% | 0.00% | 0.0% |
| Q4 2018 | $185,000 | -81.3% | 48,376 | -53.9% | 0.00% | -71.4% |
| Q3 2018 | $991,000 | – | 104,856 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |